



# The ITP Support Association

Immune thrombocytopenia

REG. CHARITY NO. 1064480

'Synehurste'  
Kimbolton Road  
Bolnhurst  
Beds  
MK44 2EW

---

Phone/fax: 0844 7770 559  
e-mail: [info@itpsupport.org.uk](mailto:info@itpsupport.org.uk)  
[www.itpsupport.org.uk](http://www.itpsupport.org.uk)

---

HON. PRESIDENT  
Professor Sir John Lilleyman  
DSc MD FRCP FRCPath FRCPC FMedSci

FOUNDER/CHIEF ADMINISTRATOR  
Shirley Watson MBE

## COMMENTS FROM THE ITP SUPPORT ASSOCIATION ON THE NICE APPRAISAL CONSULTATION DOCUMENT (2) ROMIPLOSTIM FOR THE TREATMENT OF CHRONIC IDIOPATHIC (IMMUNE) THROMBOCYTOPENIC PURPURA

### Has all of the relevant evidence been taken into account?

Yes

### Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

Para 4.2 Although para 4.2 does not specifically mention the small group of patients whose lives are devastated by frequent severe bleeding episodes The ITP Support Association is satisfied that The Committee has understood the severe nature of ITP in these patients, given the Committee's provisional recommendations.

Para 4.3 The ITP Support Association is satisfied that the Committee has understood the lack of a standard treatment pathway, and the toxicity of current treatments.

Para 4.4 The ITP Support Association is satisfied that the Committee has understood the long-term side effects of current treatments which can lead to serious chronic conditions which themselves become difficult to treat because of the underlying ITP.

Para 4.5 The ITP Support Association is satisfied that the Committee has understood that not everyone with ITP requires active treatment, and in UK clinical practice treatment is dictated by the severity of bleeding symptoms.

### Are the provisional recommendations sound and a suitable basis for guidance to the NHS?

Yes, The ITP Support Association welcomes the provisional recommendations. The committee has understood that licensed treatments for ITP are very limited and that the place for romiplostim in clinical practice will be for people with ITP whose condition is refractory to standard active treatments and rescue therapies or people who have severe disease and a high risk of bleeding that requires frequent courses of rescue therapies, i.e. as per NICE's provisional recommendations.

### Are there any aspects of the recommendations that need particular consideration to avoid unlawful discrimination against any group of people on the grounds of gender, race, disability, age, sexual orientation, religion or belief?

The committee had noted that certain religious groups may not consent to the use of blood products such as IVIG. Within this context, romiplostim can provide an alternative viable treatment intervention.

### Are there any equality -related issues that need special consideration not covered in the ACD?

No.

---

#### MEDICAL ADVISORY PANEL

Prof. Adrian Newland; Prof. James George; Prof. George Buchanan; Dr Drew Provan; Dr Paula Bolton-Maggs; Dr John Grainger; Dr Will Lester